UK: Medical Devices GSK Steps Up Inhaler Production

Editor: Alexander Stark

Glaxo Smith Kline (GSK) has opened a £ 56 million manufacturing facility in the UK to increase the production of the company’s Ellipta inhalers.

Related Vendors

GSK CEO, Andrew Witty opened the new facility in the UK.
GSK CEO, Andrew Witty opened the new facility in the UK.
(Picture: GSK)

Ware/UK – GSK said that the new facility is expected to nearly double production of Ellipta inhalers at Ware to at least 37 million per year by 2017, 95 % of which will be exported. The new facility was opened by UK life sciences minister, George Freeman and GSK chief executive officer, Andrew Witty.

The Ellipta inhaler is a multi-dose dry powder inhaler developed to deliver once-daily respiratory medicines.

“We currently export Ellipta inhalers from Ware to over 74 countries and the new facility opened today will increase capacity to meet growing demand for our new portfolio of respiratory medicines worldwide” says Andrew Witty.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent